These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37351685)

  • 1. The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.
    Henderson M; Schmidt HA; Chitembo L; Peralta H; Alaama AS; Johnson C; Baggaley R; Schaefer R
    AIDS Behav; 2023 Nov; 27(11):3755-3766. PubMed ID: 37351685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.
    Celum C; Grinsztejn B; Ngure K
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26103. PubMed ID: 37439077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provider perspectives on service delivery modifications to maintain access to HIV pre-exposure prophylaxis during the COVID-19 pandemic: qualitative results from a PrEP implementation project in Kenya.
    Velloza J; Roche SD; Owidi EJ; Irungu EM; Dollah A; Kwach B; Thuo NB; Morton JF; Mugo N; Bukusi EA; O'Malley G; Ngure K; Baeten JM; Mugwanya KK;
    J Int AIDS Soc; 2023 Feb; 26(2):e26055. PubMed ID: 36739603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis.
    Pike C; Rousseau E; Bekker LG
    South Afr J HIV Med; 2023; 24(1):1497. PubMed ID: 38089889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders.
    Heck CJ; Dam A; Yohannes K; Deacon J; Kripke K; Meyers K; Poku O; Obermeyer C; Wiant S; Quigee D; Larson M; Malati C; Sobieszczyk ME; Torres-Rueda S; Castor D
    BMJ Glob Health; 2024 May; 9(5):. PubMed ID: 38770814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences and challenges of pre-exposure prophylaxis initiation and retention among high-risk populations: qualitative insights among service providers in Thailand.
    Rayanakorn A; Chautrakarn S; Intawong K; Chariyalertsak C; Khemngern P; Olson D; Chariyalertsak S
    Front Public Health; 2024; 12():1366754. PubMed ID: 38813431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa.
    Mataboge P; Nzenze S; Mthimkhulu N; Mazibuko M; Kutywayo A; Butler V; Naidoo N; Mullick S
    Front Reprod Health; 2022; 4():1081049. PubMed ID: 36699142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Worker Perspectives of HIV Pre-exposure Prophylaxis Service Delivery in Central Uganda.
    Muwonge TR; Nsubuga R; Ware NC; Wyatt MA; Pisarski E; Kamusiime B; Kasiita V; Nalukwago GK; Brown C; Nakyanzi A; Bagaya M; Bambia F; Ssebuliba T; Katabira E; Kyambadde P; Baeten JM; Heffron R; Celum C; Mujugira A; Haberer JE
    Front Public Health; 2022; 10():658826. PubMed ID: 35444979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Online HIV prophylaxis delivery: Protocol for the ePrEP Kenya pilot study.
    Kiptinness C; Naik P; Thuo N; Malen RC; Dettinger JC; Pintye J; Rafferty M; Jomo E; Nyamasyo N; Wood T; Isabelli P; Morris S; Hattery D; Stergachis A; Were D; Sharma M; Ngure K; Mugambi ML; Ortblad KF
    Front Public Health; 2023; 11():1054559. PubMed ID: 36908449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers to and strategies for early implementation of pharmacy-delivered HIV PrEP services in Kenya: An analysis of routine data.
    Nakambale HN; Roche SD; Mogere P; Omollo V; Kuo AP; Stergachis A; Baeten JM; Bukusi E; Ngure K; Mugambi ML; Ortblad KF
    Front Reprod Health; 2023; 5():1023568. PubMed ID: 36895656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "PrEP should be available all the time and everywhere": A qualitative assessment of family planning and PrEP integration in Lesotho.
    Nonyana NM; Matete M; Lebetkin E; Yacobson I; Strachan M; Ramapepe MA; Malkin M; Chakare T
    Front Reprod Health; 2022; 4():981845. PubMed ID: 36303649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC).
    Warren M; Nyagah W; Verde Hashim C; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26094. PubMed ID: 37439050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.
    Grimsrud A; Wilkinson L; Delany-Moretlwe S; Ehrenkranz P; Green K; Murenga M; Ngure K; Otwoma NJ; Phanuphak N; Vandevelde W; Vitoria M; Bygrave H
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26095. PubMed ID: 37439076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of female sex workers on HIV pre-exposure prophylaxis delivery in Uganda: A qualitative study.
    Mpirirwe R; Mujugira A; Walusaga H; Ayebare F; Musanje K; Ndugga P; Muhumuza C; Nangendo J; Semitala FC; Kyambadde P; Kalyango J; Kiragga A; Karamagi C; Kamya MR; Armstrong-Hough M; Katahoire AR
    Res Sq; 2024 Mar; ():. PubMed ID: 38562811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Australian interdisciplinary healthcare providers' perspectives on the effects of broader pre-exposure prophylaxis (PrEP) access on uptake and service delivery: a qualitative study.
    Lazarou M; Fitzgerald L; Warner M; Downing S; Williams OD; Gilks CF; Russell D; Dean JA
    Sex Health; 2020 Dec; 17(6):485-492. PubMed ID: 33292927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.
    Mgodi NM; Murewanhema G; Moyo E; Samba C; Musuka G; Dzinamarira T; Brown JM
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26115. PubMed ID: 37439069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review.
    Vanhamel J; Rotsaert A; Reyniers T; Nöstlinger C; Laga M; Van Landeghem E; Vuylsteke B
    BMC Health Serv Res; 2020 Jul; 20(1):704. PubMed ID: 32736626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women: conflicting perspectives in South Africa.
    Nyblade L; Ndirangu JW; Speizer IS; Browne FA; Bonner CP; Minnis A; Kline TL; Ahmed K; Howard BN; Cox EN; Rinderle A; Wechsberg WM
    BMC Public Health; 2022 Oct; 22(1):1916. PubMed ID: 36242000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.